Spin-off della Kagoshima University che sviluppa virus oncolitici (serie Surv.m-CRA) con promotore della survivina.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series B Serve Biopharma raised 670 million yen in the second close of its Series B (2.17 billion cumulative) from Kyoto University Innovation Capital, Toho Holdings and others. | $4.4M |